Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.36 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.36 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.32 |
| ▸ | DRD2 | P14416 | 4/20 | 0.32 |
| ▸ | HTR2A | P28223 | 4/20 | 0.32 |
| ▸ | DRD3 | P35462 | 4/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24903989 | 0.82 | ACKR3 (0.39) | KDM4E | |
| SCHEMBL21361205 | 0.80 | CHRNB4 (0.33) | CHRNB4CHRNA3 | |
| SCHEMBL9891797 | 0.77 | KDM4E (0.51) | KDM4ECHRM1FPR2EPHX2 | |
| SCHEMBL23137982 | 0.76 | KMT2A (0.41) | EPHX2DRD2HTR2ADRD3NAMPT | |
| SCHEMBL21361191 | 0.75 | KDM5A (0.34) | KDM4ECHRNB4CHRNA3CHRM1 | |
| SCHEMBL22965461 | 0.74 | KAT2B (0.34) | KDM4E | |
| SCHEMBL19736266 | 0.74 | EPHX1 (0.41) | KDM4EEPHX2 | |
| SCHEMBL24963547 | 0.72 | EPHX1 (0.43) | KDM4EEPHX2 | |
| SCHEMBL10098777 | 0.72 | CHRNB4 (0.54) | KDM4ECHRNB4CHRNA3FPR2EPHX2 | |
| SCHEMBL16078081 | 0.71 | KDM5A (0.45) | KDM4ECHRM1FPR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2023-01-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | DTYMK, TBKBP1, NFKBIA | KDM4E 617/4885CHRNB4 3905/4885CHRNA3 3880/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.